



Louisiana Department of Health
Health Plan Advisory 17-8
Revised September 1, 2017

Single Preferred Drug List (PDL) for Selected Therapeutic Classes

The Louisiana Department of Health (LDH) planned to establish a single Preferred Drug List (PDL) for selected therapeutic classes for implementation by Managed Care Organizations (MCO) ~~shall implement it~~ effective Oct. 1, 2017.

LDH was to determine the selected therapeutic classes and drugs included. MCO Pharmacy Directors were to have worked with LDH to establish prior authorization criteria applicable to drugs included in the Single PDL for selected therapeutic classes. The criteria were to apply uniformly to all MCOs and fee for service.

MCOs were to be prohibited from entering into rebate agreements with manufacturers of drugs included in the Single PDL for selected therapeutic classes. Any current rebate agreements for drugs included in the Single PDL for selected therapeutic classes were to be discontinued before Oct. 1, 2017.

For branded products preferred in the Single PDL for selected therapeutic classes, the MCO was to consider the generic form non-preferred and ~~shall~~ not require the prescriber to indicate in writing that the branded product is medically necessary.

At this time, LDH has chosen not to implement the Single Preferred Drug List for selected therapeutic classes as previously planned.